Ceftaroline applications for therapy in the United States

Clinical Infectious Diseases

Volumn 55, Issue SUPPL. 3, 2012, Pages

  Corey, G Ralph ^a   Jones, Ronald N ^b,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JMI LABORATORIES   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAMASE; CARBAPENEMASE; CEFTAROLINE; CEFTRIAXONE; CEPHALOSPORIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL SKIN DISEASE; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; DRUG POTENCY; ENTEROBACTERIACEAE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; NOTE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; UNITED STATES;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; UNITED STATES;

EID: 84865216393     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis558     Document Type: Note

References (16)

1. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
2. ECDC. Antimicrobial resistance surveillance in Europe. 2009. Available at: http://www.ecdc.europa.eu. Accessed 21 March 2011.
3. IDSA. The 10 X ′20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 15:1081-3.
4. Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalospo-rin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2011; 52:1156-63.
5. Kaushik D, Rathi S, Jain A. Ceftaroline: a comprehensive update. Int J Antimicrob Agents 2011; 37:389-95.
6. Moellering RC Jr. Discovering new antimicrobial agents. Int J Antimi-crob Agents 2011; 37:2-9.
7. Jones RN, Farrell DJ, Mendes RE, Sader HS. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimi-crob Chemother 2011; 66 (Suppl 3):iii69-80.
8. Jones RN, Mendes RE, Sader HS. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemo-ther 2010; 65 (Suppl 4):iv17-31.
9. Karlowsky JA, Adam HJ, Decorby MR, Lagace-Wiens PR, Hoban DJZhanel GG. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients attending Canadian hospitals in 2009. Antimicrob Agents Chemother 2011; 55: 37-2846.
10. Richter SS, Heilmann KP, Dohrn CL, et al. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob Agents Chemother 2011; 55:4154-60.
11. File TM, Wilcox MH, Stein GE. Summary of ceftaroline clinical trial studies and clinical safety. Clin Infect Dis 2012. In this supplement.
12. Sader HS, Flamm RK, Farrell DJ, Jones RN. Activity results of staph-ylococcal isolates from pediatric, adult and elderly patients; AWARE ceftaroline surveillance program (USA, 2010). Clin Infect Dis 2012 In this supplement.
13. Pfaller MA, Farrell DJ, Sader HS, Jones RN. AWARE ceftaroline surveillance program (2008-2010): Trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the USA. Clin Infect Dis 2012. In this supplement.
14. Flamm RK, Sader HS, Farrell DJ, Jones RN. Variations in ceftaroline potency among nine USA census regions: Report from the 2010 AWARE program. Clin Infect Dis 2012. In this supplement.
15. Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. Ceftaro-line in vitro coverage of multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: A review of published studies and the AWARE surveillance program (2008-2010). Clin Infect Dis 2012. In this supplement.
16. Teflaro. Package insert. Forest Laboratories, revised May 2012. Available at: http://www.frx.com/pi/Teflaro-pi.pdf. Accessed 27 June 2012.